Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SATT AxLR
Montpellier, Occitania, Franceaxlr.com ↗
- Ownership
- Private
- Employees
- ~48
- Development stage
- Other
01
Overview
SATT AxLR does not develop drugs directly but accelerates academic innovations toward commercialization. It has funded 196 innovation programs and supported 134 startups since inception. Notable recent clinical progress includes licensing out preclinical peptide-based immunotherapies such as SPM001 to SPIMA Therapeutics.
- Therapeutic areas
- NeurologyPsychiatryInfectious DiseasesOncologyCardiovascular
- Modalities
- PeptidesNanobody therapyMonoclonal antibody
- Industry
- Investors
02
Partnerships
SPIMA TherapeuticsFrench public research institutionsregional universities
Beyond the preview
Go deeper on SATT AxLR.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SATT AxLR.